EXEL

SEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.22 to $18.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000079 · wf-form4_162933099603526.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000074 · wf-form4_162751718585473.xml · derivative · entry 3

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2023-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.

SEC source: 0000939767-21-000074 · wf-form4_162751718585473.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 689,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000073 · wf-form4_162708405215652.xml · derivative · entry 3

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 35,000 shares

Expires 2023-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.

SEC source: 0000939767-21-000073 · wf-form4_162708405215652.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 649,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 60,000 shares

Expires 2022-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.22 to $17.63. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000072 · wf-form4_162647991700323.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000071 · wf-form4_162578790212808.xml · derivative · entry 4

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2023-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016.

SEC source: 0000939767-21-000071 · wf-form4_162578790212808.xml · derivative · entry 3

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2022-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015.

SEC source: 0000939767-21-000071 · wf-form4_162578790212808.xml · nonDerivative · entry 2

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000071 · wf-form4_162578790212808.xml · nonDerivative · entry 1

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · derivative · entry 4

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 60,000 shares

Expires 2022-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 175,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · nonDerivative · entry 2

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,467

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.90 to $22.40. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000070 · wf-form4_162440660264370.xml · nonDerivative · entry 1

Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 215,102 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000067 · wf-form4_162224865729824.xml · derivative · entry 2

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,598

Underlying: Common Stock · 16,598 shares

Expires 2028-05-26

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000067 · wf-form4_162224865729824.xml · nonDerivative · entry 1

WYSZOMIERSKI JACK L · CIK 0001023225 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,888

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 8,299 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000066 · wf-form4_162224849162336.xml · derivative · entry 1

FELDBAUM CARL B · CIK 0001326377 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,549

Underlying: Common Stock · 33,549 shares

Expires 2028-05-26

F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000065 · wf-form4_162224835853171.xml · derivative · entry 1

WILLSEY LANCE · CIK 0001202106 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,549

Underlying: Common Stock · 33,549 shares

Expires 2028-05-26

F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000064 · wf-form4_162224807212123.xml · derivative · entry 2

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,598

Underlying: Common Stock · 16,598 shares

Expires 2028-05-26

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000064 · wf-form4_162224807212123.xml · nonDerivative · entry 1

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,414

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 8,299 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000063 · wf-form4_162224794151373.xml · nonDerivative · entry 1

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,304,551

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000062 · wf-form4_162224769762279.xml · derivative · entry 2

Freire Maria C · CIK 0001547999 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,598

Underlying: Common Stock · 16,598 shares

Expires 2028-05-26

F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000062 · wf-form4_162224769762279.xml · nonDerivative · entry 1

Freire Maria C · CIK 0001547999 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,126

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 11,829 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000061 · wf-form4_162224756375597.xml · derivative · entry 1

COHEN CHARLES · CIK 0001202089 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,549

Underlying: Common Stock · 33,549 shares

Expires 2028-05-26

F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000060 · wf-form4_162224738849446.xml · derivative · entry 1

Garber Alan M · CIK 0001312907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,549

Underlying: Common Stock · 33,549 shares

Expires 2028-05-26

F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date.

SEC source: 0000939767-21-000059 · wf-form4_162224717088166.xml · nonDerivative · entry 1

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,614

F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000058 · wf-form4_162224691723172.xml · nonDerivative · entry 1

Smith Julie · CIK 0001557928 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,725

F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.

F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date.

F3 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000055 · wf-form4_162138317439427.xml · nonDerivative · entry 2

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,994

SEC source: 0000939767-22-000114 · wf-form4_166873595249414.xml · nonDerivative · entry 1

Hessekiel Jeffrey · CIK 0001599803 · EVP, General Counsel & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 604,822

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2020.

F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.09 to $25.71. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3 · balance_after: Includes 144,674 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 18 shares of common stock acquired on October 31, 2022, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

SEC source: 0000939767-21-000055 · wf-form4_162138317439427.xml · nonDerivative · entry 1

Haley Patrick J. · CIK 0001692954 · EVP, Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,587

F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded February 19, 2020.

F2 · balance_after: Includes 221,640 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,221 shares of Exelixis, Inc. common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · nonDerivative · entry 5

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,038,789

F5 · kind: On May 14, 2021, the Reporting Person gifted 19,722 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · nonDerivative · entry 4

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,813

F5 · kind: On May 14, 2021, the Reporting Person gifted 19,722 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Trust dated July 21, 1994, as amended.

SEC source: 0000939767-21-000053 · wf-form4_162129678672791.xml · derivative · entry 3

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2023-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016.

SEC source: 0000939767-21-000053 · wf-form4_162129678672791.xml · nonDerivative · entry 2

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,115

SEC source: 0000939767-21-000053 · wf-form4_162129678672791.xml · nonDerivative · entry 1

MARCHESI VINCENT T · CIK 0001202095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000052 · wf-form4_162129669367535.xml · nonDerivative · entry 1

POSTE GEORGE · CIK 0001180770 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,190

F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.94 to $25.05. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.

F2 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · derivative · entry 4

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 100,000 shares

Expires 2022-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 250,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

SEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · nonDerivative · entry 2

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,078

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.15 to $25.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

SEC source: 0000939767-21-000050 · wf-form4_162103888892358.xml · nonDerivative · entry 1

Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 714,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 596 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · derivative · entry 7

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 50,000 shares

Expires 2023-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 150,000 shares of Common Stock, became fully exercisable on February 11, 2020.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · nonDerivative · entry 3

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511,535

F4 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 19,722 shares of Common Stock on the net exercise of a stock option to purchase 50,000 shares of Common Stock. The Issuer withheld 30,278 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on May 12, 2021 of $25.16.

SEC source: 0000939767-21-000051 · wf-form4_162103985398361.xml · nonDerivative · entry 2

MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 541,813

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · balance_after: Includes 491,813 shares of Common Stock that will be issued to the Reporting Person upon vesting of restricted stock units.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · derivative · entry 9

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2021-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · derivative · entry 8

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2022-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · derivative · entry 7

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2023-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 6

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,288,127

F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.99 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 5

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,293,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000939767-21-000049 · wf-form4_162095233683684.xml · nonDerivative · entry 4

PAPADOPOULOS STELIOS · CIK 0001202098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,253,600

F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.98 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.